Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)
Immunotherapy, as the fourth largest anti-tumor treatment method, has made breakthrough progress in the field of cancer treatment. Checkpoint inhibitors have been widely used in the treatment of various malignant tumors, and a lot of clinical evidence and experience have also been accumulated in the...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Editorial Office of China Oncology
2023-10-01
|
| Series: | Zhongguo aizheng zazhi |
| Subjects: | |
| Online Access: | http://www.china-oncology.com/fileup/1007-3639/PDF/1698723455992-12434734.pdf |
| _version_ | 1827345258975854592 |
|---|---|
| author | Society of Onco-Endocrinology of Chinese Anti-Cancer Association |
| author_facet | Society of Onco-Endocrinology of Chinese Anti-Cancer Association |
| author_sort | Society of Onco-Endocrinology of Chinese Anti-Cancer Association |
| collection | DOAJ |
| description | Immunotherapy, as the fourth largest anti-tumor treatment method, has made breakthrough progress in the field of cancer treatment. Checkpoint inhibitors have been widely used in the treatment of various malignant tumors, and a lot of clinical evidence and experience have also been accumulated in the field of gynecological malignant tumors. However, there is still a lack of standardization in the application of immunotherapy such as immune checkpoint inhibitors for the treatment of gynecological malignant tumors. Therefore, led by the Cancer Endocrine Professional Committee of the China Anti-Cancer Association, experts from multiple fields were organized to use high-quality clinical research results as well as the results of the 2023 American Society of Clinical Oncology (ASCO) conference as evidence. Through discussion and voting, the consensus of Chinese experts on immunotherapy for gynecological malignant tumors (2023 version) has been formed. This consensus recommended the clinical application of immune checkpoint inhibitors for the classification of common gynecological cervical cancer, endometrial cancer, ovarian cancer and other malignant tumors, such as single drug or combination chemotherapy, targeted therapy, etc. It summarized the research and application of tumor vaccines, adoptive cell immunotherapy and cytokine immunotherapy in gynecological malignant tumors, and provided reference for domestic peers, in order to further standardize the clinical practice of immunotherapy for gynecological malignant tumors. |
| first_indexed | 2024-03-07T23:04:02Z |
| format | Article |
| id | doaj.art-46773105c54344f985701b8c7a488947 |
| institution | Directory Open Access Journal |
| issn | 1007-3639 |
| language | English |
| last_indexed | 2024-03-07T23:04:02Z |
| publishDate | 2023-10-01 |
| publisher | Editorial Office of China Oncology |
| record_format | Article |
| series | Zhongguo aizheng zazhi |
| spelling | doaj.art-46773105c54344f985701b8c7a4889472024-02-22T06:28:14ZengEditorial Office of China OncologyZhongguo aizheng zazhi1007-36392023-10-01331095496710.19401/j.cnki.1007-3639.2023.10.008Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)Society of Onco-Endocrinology of Chinese Anti-Cancer AssociationImmunotherapy, as the fourth largest anti-tumor treatment method, has made breakthrough progress in the field of cancer treatment. Checkpoint inhibitors have been widely used in the treatment of various malignant tumors, and a lot of clinical evidence and experience have also been accumulated in the field of gynecological malignant tumors. However, there is still a lack of standardization in the application of immunotherapy such as immune checkpoint inhibitors for the treatment of gynecological malignant tumors. Therefore, led by the Cancer Endocrine Professional Committee of the China Anti-Cancer Association, experts from multiple fields were organized to use high-quality clinical research results as well as the results of the 2023 American Society of Clinical Oncology (ASCO) conference as evidence. Through discussion and voting, the consensus of Chinese experts on immunotherapy for gynecological malignant tumors (2023 version) has been formed. This consensus recommended the clinical application of immune checkpoint inhibitors for the classification of common gynecological cervical cancer, endometrial cancer, ovarian cancer and other malignant tumors, such as single drug or combination chemotherapy, targeted therapy, etc. It summarized the research and application of tumor vaccines, adoptive cell immunotherapy and cytokine immunotherapy in gynecological malignant tumors, and provided reference for domestic peers, in order to further standardize the clinical practice of immunotherapy for gynecological malignant tumors.http://www.china-oncology.com/fileup/1007-3639/PDF/1698723455992-12434734.pdf|immunotherapy|gynecological malignant tumors|immune checkpoint inhibitors |
| spellingShingle | Society of Onco-Endocrinology of Chinese Anti-Cancer Association Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) Zhongguo aizheng zazhi |immunotherapy|gynecological malignant tumors|immune checkpoint inhibitors |
| title | Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) |
| title_full | Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) |
| title_fullStr | Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) |
| title_full_unstemmed | Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) |
| title_short | Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition) |
| title_sort | chinese expert consensus on immunotherapy for gynecological malignant tumors 2023 edition |
| topic | |immunotherapy|gynecological malignant tumors|immune checkpoint inhibitors |
| url | http://www.china-oncology.com/fileup/1007-3639/PDF/1698723455992-12434734.pdf |
| work_keys_str_mv | AT societyofoncoendocrinologyofchineseanticancerassociation chineseexpertconsensusonimmunotherapyforgynecologicalmalignanttumors2023edition |